Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
株式のランク
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
株価
$4.48
時価総額
$4.99B
変化（1日）
-5.20%
変化（1年）
-41.89%
国
CN
取引 Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
カテゴリー
Healthcare
Shenzhen Salubris Pharmaceuticals Co., Ltd.（002294）の利益
Jun 2026 時点の利益 TTM: $95.41M
Shenzhen Salubris Pharmaceuticals Co., Ltd. の最新の財務報告によると、同社の現在の利益は $95.41M です。2024 年には $86.66M の利益を上げ、これは 2023 年の利益 $90.66M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Shenzhen Salubris Pharmaceuticals Co., Ltd. の利益の推移（2006 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $95.41M | 1.77% |
| 2025 | $93.75M | 8.18% |
| 2024 | $86.66M | -4.42% |
| 2023 | $90.66M | -12.38% |
| 2022 | $103.47M | 9.64% |
| 2021 | $94.38M | 986.53% |
| 2020 | $8.69M | -92.90% |
| 2019 | $122.26M | -50.71% |
| 2018 | $248.05M | -5.91% |
| 2017 | $263.64M | 10.90% |
| 2016 | $237.72M | 3.50% |
| 2015 | $229.68M | 16.86% |
| 2014 | $196.54M | 22.09% |
| 2013 | $160.97M | 33.79% |
| 2012 | $120.32M | 59.83% |
| 2011 | $75.28M | 19.59% |
| 2010 | $62.95M | 72.35% |
| 2009 | $36.52M | 96.81% |
| 2008 | $18.56M | 76.92% |
| 2007 | $10.49M | 123.31% |
| 2006 | $4.70M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $3.62B | 3,693.17% |
US
|
|
| $4.11B | 4,206.59% |
FR
|
|
| - | - |
JP
|
|
| $1.59B | 1,566.52% |
US
|
|
| - | - |
CH
|
